EMEA-001792-PIP01-15
Key facts
| Active substance |
Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human Wiskott Aldrich Syndrome (WAS) cDNA sequence
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0083/2016
|
| PIP number |
EMEA-001792-PIP01-15
|
| Pharmaceutical form(s) |
Dispersion for infusion
|
| Condition(s) / indication(s) |
Treatment of Wiskott Aldrich Syndrome
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
GlaxoSmithKline Trading Services Limited
Tel. +1 4388998201 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|
| Compliance procedure number |
EMEA-001792-PIP01-15
|
| Compliance opinion date |
24/03/2017
|
| Compliance outcome |
positive
|